Bio-Path Holdings, Inc.

BPTH · OTC · United States

Share price · BPTH

$0.03-0.01 (-25.00%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BPTH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Jun 2026+66.7%
  2. 5 Jun 2026+33.3%
  3. 1 Jun 2026+33.3%
  4. 22 May 2026+33.3%
  5. 20 May 2026+50.0%
  6. 19 May 2026-50.0%
  7. 15 May 2026+33.3%
  8. 13 May 2026-25.0%
  9. 12 May 2026-20.0%

    Nothing announced by BPTH that day or the session before.

  10. 8 May 2026-16.7%

    Nothing announced by BPTH that day or the session before.

Share of unusual movement by asset

For each asset, the share of BPTH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
GRB2 (growth factor receptor-bound protein 2) mRNARNA / oligonucleotide
Acute Myeloid Leukemia
Phase 1
BCL2 mRNARNA / oligonucleotide
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
PrexigebersenPhase 2Acute Myeloid Leukemia (AML)
Est. primary completion 2027-12 · NCT02781883 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—<$0.1M<$0.1M$0.3M-<$0.1M operating cash flowreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3—$0.3M—$1.0M$0 operating cash flowreport ↗
2025-Q2—$4.0M$0$4.6M-$0.3M operating cash flowreport ↗
2025-Q1—$2.0M$0.1M$2.9M-$1.3M operating cash flowreport ↗
2024-Q3—$1.3M$0.6M$2.1M-$3.4M operating cash flowreport ↗
2024-Q2—$1.9M$4.0M$1.9M-$4.3M operating cash flowreport ↗
2024-Q1—$2.3M$0.2M$3.2M-$1.0M operating cash flowreport ↗
2023-Q3—$2.3M$2.4M$3.2M-$2.8M operating cash flowreport ↗
2023-Q2—$3.0M$3.4M$4.2M-$3.3M operating cash flowreport ↗
2023-Q1—$4.0M$6.7M$5.3M-$3.6M operating cash flowreport ↗
2022-Q3—$2.4M$14M$3.5M-$3.4M operating cash flowreport ↗
2022-Q2—$1.9M$17M$3.0M-$4.2M operating cash flowreport ↗
2022-Q1—$2.1M$21M$3.4M-$2.5M operating cash flowreport ↗
2021-Q3—$1.0M$27M$2.1M-$2.9M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$7.3M$1.2M$2.5M-$11M operating cash flowreport ↗

Bio-Path Holdings reported revenue was not disclosed for the full year 2024. R&D expense was $7.3 million, down 37.1% YoY, and cash and equivalents stood at $1.2 million. The company reported a net loss of $9.9 million, or $4.12 per share, for the year.

Bio-Path highlighted progress across its obesity and oncology programs, including preclinical results for BP1001-A in obesity and Type 2 diabetes showing restored insulin sensitivity in cell models. The company expanded its global patent portfolio with newly issued patents in the U.S. and New Zealand, and provided an update from the Phase 1/1b trial of BP1002 in refractory/relapsed acute myeloid leukemia, which has advanced to the fourth dose cohort of 90 mg/m².

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$12M$1.1M$4.0M-$12M operating cash flowreport ↗
2022-FY—$9.2M$10M$3.5M-$15M operating cash flowreport ↗
2021-FY—$5.9M$24M$2.6M-$9.9M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2024-07-30Nielsen Peter Henry · director, President, CEO & CFOAward / grant (derivative)25,000——Form 4
2024-07-30MORRIS DOUGLAS P · directorAward / grant (derivative)3,537——Form 4
2024-07-30Cleaver Heath · directorAward / grant (derivative)2,000——Form 4
2024-07-30Aubert Paul · directorAward / grant (derivative)2,000——Form 4
2024-07-30Sherwood Aline · directorAward / grant (derivative)2,000——Form 4
2023-05-02Nielsen Peter Henry · director, President, CEO & CFOAward / grant (derivative)105,000——Form 4
2023-05-02MORRIS DOUGLAS P · directorAward / grant (derivative)13,000——Form 4
2023-05-02Sherwood Aline · directorAward / grant (derivative)10,000——Form 4